Růstový faktor-19 fibroblastu: vývoj, analytická charakteristika a klinické hodnocení nového testu ELISA

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15510%2F08%3A00006467" target="_blank" >RIV/61989592:15510/08:00006467 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/62157124:16370/08:00002062

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Fibroblast growth factor-19: Development, analytical characterization and clinical evaluation of a New ELISA Test

Popis výsledku v původním jazyce

Background: Fibroblast growth factor 19 (FGF-19) is a potent metabolic regulator which influences glucose and lipid homeostasis. Aim: To develop an ELISA assay for measuring FGF-19 in human serum, and to investigate its concentrations in healthy volunteers and patients suffering from the metabolic syndrome. Material and Methods: A sandwich ELISA method was developed for quantitative determination of human FGF-19 in serum samples. Blood pressure, waist circumference, FGF-21 serum levels, serum cholesterol, triacylglycerols, HDL-cholesterol, LDL-cholesterol, insulin, glucose, adiponectin, uric acid, creatinine, hs-CRP and calculated BMI and Quicki insulin sensitivity index were measured in 153 healthy volunteers and in 66 persons with the metabolic syndrome. Results: Sex or age did not influence FGF-19 serum concentrations in the healthy volunteers. Probands with the metabolic syndrome had had 65% lower FGF-19 serum values than the healthy ones (medians 158.6 vs. 242.4 ng/L; p<0.01). FGF

Název v anglickém jazyce

Fibroblast growth factor-19: Development, analytical characterization and clinical evaluation of a New ELISA Test

Popis výsledku anglicky

Background: Fibroblast growth factor 19 (FGF-19) is a potent metabolic regulator which influences glucose and lipid homeostasis. Aim: To develop an ELISA assay for measuring FGF-19 in human serum, and to investigate its concentrations in healthy volunteers and patients suffering from the metabolic syndrome. Material and Methods: A sandwich ELISA method was developed for quantitative determination of human FGF-19 in serum samples. Blood pressure, waist circumference, FGF-21 serum levels, serum cholesterol, triacylglycerols, HDL-cholesterol, LDL-cholesterol, insulin, glucose, adiponectin, uric acid, creatinine, hs-CRP and calculated BMI and Quicki insulin sensitivity index were measured in 153 healthy volunteers and in 66 persons with the metabolic syndrome. Results: Sex or age did not influence FGF-19 serum concentrations in the healthy volunteers. Probands with the metabolic syndrome had had 65% lower FGF-19 serum values than the healthy ones (medians 158.6 vs. 242.4 ng/L; p<0.01). FGF

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

ED - Fyziologie

OECD FORD obor

—

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2008

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Scandinavian Journal of Clinical and Laboratory Investigation

ISSN

0036-5513

e-ISSN

—

Svazek periodika

68

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—